- Home
- XTNT vs CTSO Comparison
XTNT vs CTSO Comparison
Compare XTNT & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- CTSO
- Stock Information
- Founded
- XTNT N/A
- CTSO 1997
- Country
- XTNT United States
- CTSO United States
- Employees
- XTNT N/A
- CTSO N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- CTSO Medical/Dental Instruments
- Sector
- XTNT Health Care
- CTSO Health Care
- Exchange
- XTNT Nasdaq
- CTSO Nasdaq
- Market Cap
- XTNT 60.9M
- CTSO 61.3M
- IPO Year
- XTNT N/A
- CTSO N/A
- Fundamental
- Price
- XTNT $0.47
- CTSO $0.99
- Analyst Decision
- XTNT Strong Buy
- CTSO Strong Buy
- Analyst Count
- XTNT 1
- CTSO 3
- Target Price
- XTNT $3.00
- CTSO $4.67
- AVG Volume (30 Days)
- XTNT 33.3K
- CTSO 73.4K
- Earning Date
- XTNT 03-06-2025
- CTSO 05-08-2025
- Dividend Yield
- XTNT N/A
- CTSO N/A
- EPS Growth
- XTNT N/A
- CTSO N/A
- EPS
- XTNT N/A
- CTSO N/A
- Revenue
- XTNT $117,267,000.00
- CTSO $35,594,520.00
- Revenue This Year
- XTNT $15.56
- CTSO $24.50
- Revenue Next Year
- XTNT $22.39
- CTSO $21.77
- P/E Ratio
- XTNT N/A
- CTSO N/A
- Revenue Growth
- XTNT 28.44
- CTSO 14.51
- 52 Week Low
- XTNT $0.33
- CTSO $0.70
- 52 Week High
- XTNT $1.14
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- XTNT 45.30
- CTSO 42.83
- Support Level
- XTNT $0.45
- CTSO $0.97
- Resistance Level
- XTNT $0.51
- CTSO $1.05
- Average True Range (ATR)
- XTNT 0.04
- CTSO 0.07
- MACD
- XTNT 0.00
- CTSO -0.01
- Stochastic Oscillator
- XTNT 36.55
- CTSO 12.37
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.